Antitumor activity
NSCLC, esophageal cancer, SCLC, NPC, SD, PD, small-cell lung cancer
SCLC, OESOPHAGEAL CANCER, DISEASE, SOLID TUMORS, NASOPHARYNGEAL CARCINOMA, NSCLC
As of data cutoff (14 July 2022), a PR was observed in seven patients (20.0%): five with NSCLC (one patient had a PR after PD) and two with nasopharyngeal carcinoma (NPC). SD was achieved in five patients (14.3%): two with NSCLC, one with esophageal cancer (EC), one with small-cell lung cancer (SCLC), and one with NPC (Efficacy of QL1604 in patients with advanced solid tumors (full analysis set).CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, objective response rate; CI, confidence interval; DCR, disease control rate.a. ORR was defined as the proportion of patients who had a CR or PR as best response per RECIST version 1.1 by investigator.b. DCR was defined as the proportion of patients who had a CR, PR, or SD as best response per RECIST version 1.1 by investigator.c. The 95% CI was calculated by using the Clopper–Pearson method.